ASXC (TransEnterix) Company Net Assets

Asensus Surgical, Inc. (ASXC) develops Senhance robots for minimally invasive surgeries, and the acquisition by KARL STORZ at $0.35 per share eliminated the threat of default. The company is currently undergoing the merger process with its new owner, as confirmed by the market value visualization on GURU.Markets, where the indicator equals -0.01. Revenues rely on service maintenance, which mitigates potential delays in the procurement of expensive systems by clinics.

Book value capitalization reflects the value of net assets minus all liabilities, determining the real asset base of each share regardless of market volatility. By analyzing the company's book capitalization, an investor sees the material foundation of Asensus Surgical, Inc. (ASXC), which is being strengthened through technological synergy and the implementation of robot-assisted systems in partnership with leading clinics.